Dr. Richardson on Phase 1 Data With CC-92480 in Multiple Myeloma

Paul G. Richardson, MD, discusses phase 1 data (NCT03374085) with CC-92480 in multiple myeloma.

Paul G. Richardson, MD, clinical program leader and director of clinical research, Jerome Lipper Multiple Myeloma Center, and institute physician, Dana-Farber Cancer Institute, and RJ Corman Professor of Medicine at Harvard Medical School, discusses phase 1 data (NCT03374085) with CC-92480 in multiple myeloma.

In an ongoing phase 1 trial, CC-92480 in combination with dexamethasone showed favorable activity and safety in patients with heavily pretreated relapsed/refractory multiple myeloma. The overall response rate was 21.1%.

At the time of data cutoff, approximately one-third of patients remained on study. The majority of treatment-related discontinuations were due to progressive disease, says Richardson. There have been no treatment-related deaths.

Dose-limiting toxicities, which included neutropenia and thrombocytopenia, were manageable with dose reductions, schedule modifications, and supportive care, says Richardson. The maximum-tolerated dose was determined to be 1 mg once daily.

<<< 2020 ASCO Virtual Scientific Program

Related Videos
Sarah Ackroyd, MD, MPH, fellow, gynecologic oncology, University of Chicago Medical Center,
Beryl Manning-Geist, MD
Jung-Yun Lee, MD, PhD
Brian Mitzman, MD, FACS, FCCP
Andrew Kin, MD
Nathalie McDowell Johnson, MD, FACS
Meghan K. Berkenstock, MD
Ursula A. Matulonis, MD
Cara A. Mathews, MD
William M. Sikov, MD
Related Content